Nature Reviews Clinical Oncology最新文献_第2页

A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions. 2026年骨髓增生异常肿瘤的最新进展：现状、挑战和未来方向

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-14 DOI: 10.1038/s41571-026-01141-2

Jan Philipp Bewersdorf,Alain Mina,Maximilian Stahl,Amer M Zeidan

{"title":"A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.","authors":"Jan Philipp Bewersdorf,Alain Mina,Maximilian Stahl,Amer M Zeidan","doi":"10.1038/s41571-026-01141-2","DOIUrl":"https://doi.org/10.1038/s41571-026-01141-2","url":null,"abstract":"Myelodysplastic neoplasms, also known as myelodysplastic syndromes (MDS), are a heterogeneous group of myeloid malignancies characterized by ineffective haematopoiesis, cytopenias and a variably increased risk of progression to acute myeloid leukaemia. MDS primarily affect older adults with a median age at diagnosis of 76 years among patients in the USA. Despite major advances in our understanding of the genetic landscape and pathophysiology of MDS over the past 20 years, few disease-modifying therapies have been approved. Allogeneic haematopoietic stem cell transplantation remains the only potentially curative option. This slow therapeutic progress likely reflects the complex and widely heterogeneous pathophysiology of MDS, including a multifaceted interplay of somatic and germline mutations, a dysfunctional immune system, and an inflamed bone marrow microenvironment. Despite improvements in diagnostic tools, classification systems and prognostic models, these changes have introduced challenges for clinical trial design and epidemiological reporting. In this Review, we provide an update on the epidemiology, diagnosis, risk stratification, classification and expanding therapeutic armamentarium for the management of MDS. We also provide an overview of the current challenges to further progress and discuss future directions of research, which will hopefully lead to the development and approval of novel and effective therapies.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"52 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147680608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidisciplinary management of meningiomas in the era of precision oncology. 精准肿瘤学时代脑膜瘤的多学科治疗。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-13 DOI: 10.1038/s41571-026-01148-9

Majid Assadi,Malik E Juweid,Philipp Lohmann,Giuseppe Minniti,Felix Sahm,Jana Ivanidze,Philipp Karschnia,Alexander Landry,Felix M Mottaghy,Gelareh Zadeh

{"title":"Multidisciplinary management of meningiomas in the era of precision oncology.","authors":"Majid Assadi,Malik E Juweid,Philipp Lohmann,Giuseppe Minniti,Felix Sahm,Jana Ivanidze,Philipp Karschnia,Alexander Landry,Felix M Mottaghy,Gelareh Zadeh","doi":"10.1038/s41571-026-01148-9","DOIUrl":"https://doi.org/10.1038/s41571-026-01148-9","url":null,"abstract":"Meningiomas are the most common type of primary intracranial tumour. Histopathology-based WHO grading remains the standard for guiding management in most institutions, although new molecularly driven classification tools have been shown to improve prognostic accuracy and could guide personalized management decisions. Somatostatin receptor-targeted PET-CT or MRI has improved tumour delineation, enabling earlier diagnosis of residual or recurrent disease and guiding precision delivery of local therapies. Patients with meningioma have been traditionally managed with surgery and radiotherapy, although advances over the past decade have brought about promising novel treatment options. These developments include endoscopic surgery and other forms of minimally invasive surgery that have enabled safer resections, stereotactic radiotherapy platforms and systemic treatment with targeted agents, immune checkpoint inhibitors and targeted radioligands, which are being increasingly considered for patients with meningioma. Despite these advances, challenges remain, particularly in the standardization of classification systems, development of predictive biomarkers and optimization of trial designs. In this comprehensive, state-of-the-art Review we provide an integrated roadmap for meningioma care as well as a framework for ongoing and future research in this field.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"431 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147666511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cultivating the microbiome to enhance cancer immunotherapy. 培养微生物群增强癌症免疫治疗。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-09 DOI: 10.1038/s41571-026-01146-x

Erez N Baruch,Nadim J Ajami,Jennifer A Wargo

引用次数: 0

A prioritization framework for large-scale cancer screening under resource constraints: three 'not all' principles. 资源限制下大规模癌症筛查的优先排序框架：三个“非全部”原则。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-03-26 DOI: 10.1038/s41571-026-01144-z

Xuesi Dong,Yu Wang,Ni Li

引用次数: 0

In what clinical settings are the MASAI trial results applicable? MASAI试验结果适用于哪些临床环境？

IF 82.2 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-03-24 DOI: 10.1038/s41571-026-01143-0

Karla Kerlikowske, Kathryn P. Lowry, Diana L. Miglioretti

引用次数: 0

Neoadjuvant GOLP is effective in high-risk intrahepatic cholangiocarcinoma. 新辅助GOLP治疗高危肝内胆管癌有效。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-03-18 DOI: 10.1038/s41571-026-01142-1

Diana Romero

引用次数: 0

Author Correction: Innovative approaches for lung cancer screening and interception 作者更正：肺癌筛查和拦截的创新方法。

IF 82.2 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-03-10 DOI: 10.1038/s41571-026-01140-3

Jianjun Zhang, Matthew D. Park, Tej Pandya, Elaine Shum, Jia Wu, Simon Heeke, Ramin Salehi-Rad, Thomas U. Marron, Zhubo Wei, Hui Li, Torsten G. Blum, John V. Heymach, Steven M. Dubinett, Pan-Chyr Yang, Charles Swanton, Miriam Merad

引用次数: 0

Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics. 转移性胃癌的治疗进展：当前的策略和新兴的治疗方法。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-03-10 DOI: 10.1038/s41571-026-01134-1

Joan Choo,Amalya Sargsyan,Vahe Khachatryan,Sara Lonardi,Filippo Pietrantonio,Raghav Sundar,Samuel Klempner,Yelena Janjigian

{"title":"Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics.","authors":"Joan Choo,Amalya Sargsyan,Vahe Khachatryan,Sara Lonardi,Filippo Pietrantonio,Raghav Sundar,Samuel Klempner,Yelena Janjigian","doi":"10.1038/s41571-026-01134-1","DOIUrl":"https://doi.org/10.1038/s41571-026-01134-1","url":null,"abstract":"Metastatic gastric cancer remains a major global health challenge with poor long-term outcomes. Over the past 5 years, the treatment landscape has rapidly evolved with the integration of biomarker-informed strategies that guide the use of immune checkpoint inhibitors and targeted therapies in molecularly defined subgroups, including microsatellite unstable, PD-L1-expressing, HER2-positive and claudin 18.2-positive disease. Standard first-line treatment continues to rely on fluoropyrimidine-platinum chemotherapy backbones, with biomarker-driven agents selectively layered on for improved efficacy. Despite these advances, most patients continue to have disease progression, and durable responses are uncommon. In addition to identifying and validating new targets such as FGFR2b, ongoing efforts are focusing on novel strategies involving established targets, including HER2 and claudin 18.2, using next-generation treatment modalities such as antibody-drug conjugates, bispecific antibodies and cellular therapies. Complementary platforms including circulating tumour DNA and theranostic agents are also being explored to better guide treatment selection, facilitate non-invasive monitoring and enable early response assessments. In this Review, we summarize the current standard of care for patients with metastatic gastric cancer and also highlight emerging approaches aimed at improving the outcomes in these patients.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"80 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147383479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown. 胰高血糖素样肽1受体激动剂与癌症风险：好，坏和未知。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-03-09 DOI: 10.1038/s41571-026-01135-0

Edoardo Mannucci,Ilaria Dicembrini

{"title":"Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown.","authors":"Edoardo Mannucci,Ilaria Dicembrini","doi":"10.1038/s41571-026-01135-0","DOIUrl":"https://doi.org/10.1038/s41571-026-01135-0","url":null,"abstract":"Glucagon-like peptide 1 receptor agonists (GLP1RAs) are widely used for the treatment of type 2 diabetes mellitus (T2DM) and, at higher doses, obesity. Both T2DM and obesity are associated with a higher risk of cancer, which can be reduced by intentional weight loss, whereas effects of a reduction in hyperglycaemia are uncertain. GLP1RAs might have further direct effects, either beneficial or detrimental, on the development of specific malignancies. Evidence from preclinical and clinical studies suggests heterogeneous effects of GLP1RAs on cancer risk: the incidence of hepatocellular, oesophageal, endometrial, ovarian and prostate cancers might be reduced, whereas safety concerns persist with respect to thyroid (both medullary and non-medullary) carcinomas. Conversely, initial concerns on the risk of pancreatic cancer have not been confirmed. Nonetheless, the interpretation of current data is limited by detection and prescription biases in observational studies as well as insufficient follow-up and number of events in randomized trials. In this Review, we summarize current preclinical and clinical evidence, showing that the risk-benefit profile of GLP1RAs remains favourable in individuals with T2DM and obesity, although caution is warranted in those with a low cardiometabolic risk, for whom the potential risks of cancer might outweigh any expected benefits; conversely, the potential use of GLP1RAs as adjuvant therapies for certain forms of cancer needs to be further investigated.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"1 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147381176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The changing landscape of oncology clinical trials in Latin America 拉丁美洲肿瘤临床试验的变化。

IF 82.2 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-03-04 DOI: 10.1038/s41571-026-01137-y

Andreia Cristina de Melo

引用次数: 0